๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

30 recruiting trials

for Advanced Triple Negative Breast Cancer

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer NCT01042379Phase 242 sites๐Ÿ“ Birmingham๐Ÿ“ Scottsdale๐Ÿ“ Tucson QuantumLeap Healthcare Collaborative ยท Tests: Standard Therapy, AMG 386 with or without Trastuzumab, AMG 479 (Ganitumab) plus Metformin, MK-2206 with or without Trasโ€ฆ A Prospective, Open-label, Single-arm, Exploratory Clinical Trial to Evaluate the Safety and Tolerability of 225Ac-TR2205 Injection in Patients With Triple-negative Breast Cancer. NCT07340424EARLY Phase 11 site๐Ÿ“ Jinan Xiaorong Sun ยท Tests: 225Ac-TR2205 Injection Efficacy and Safety of Extended-Dose Interval Immunotherapy Versus Standard-Dose Interval Immunotherapy for Advanced Triple-Negative Breast Cancer NCT07401537Phase 21 site๐Ÿ“ Guangzhou Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University ยท Tests: Extended-Dose Interval Immunotherapy, Standard-Dose Interval Immunotherapy Evaluating the Safety, Tolerability, and Preliminary Anti-tumor Activity of MB0151 in Adult Subjects With Advanced Solid Tumors Expressing Somatostatin Receptors NCT06840821Phase 1, Phase 21 site๐Ÿ“ Jinan Mainline Biosciences (Shanghai) Co., Ltd ยท Tests: MB0151 for injection First-Line Sacituzumab Govitecan in Advanced Untreated Triple-Negative Breast Cancer Patients. NCT07299409Phase 21 site๐Ÿ“ Vancouver Nathalie Levasseur ยท Tests: Sacituzumab Govitecan (SG) AK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/ Metastatic Triple-negative Breast Cancer NCT06767527Phase 31 site๐Ÿ“ Beijing Akeso ยท Tests: AK112, Nab-paclitaxel, Placebo A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors NCT04895709Phase 1, Phase 247 sites๐Ÿ“ Clovis๐Ÿ“ Los Angeles๐Ÿ“ Newport Beach Bristol-Myers Squibb ยท Tests: BMS-986340, BMS-936558-01, Docetaxel, Pumitamig A Multicenter, Prospective, Cohort Study of Trop-2 ADC Combination Therapy for Advanced Triple-negative Breast Cancer NCT06878625Phase 21 site๐Ÿ“ Tianjin Tianjin Medical University Cancer Institute and Hospital ยท Tests: Sacituzumab Govitecan combined with Toripalimab, Sacituzumab govitecan combined with anti-angiogenesis Atezolizumab and Chemotherapy Treatment as T-cell Activators in Metastatic Triple Negative Breast Cancer Patients NCT06690840Phase 25 sites๐Ÿ“ Monza๐Ÿ“ Roma๐Ÿ“ Roma European Institute of Oncology ยท Tests: Atezolizumab in combination with Cyclophosphamide and Vinorelbine PQ203 in Advanced Malignant Tumors Including Triple Negative Breast Cancer NCT07190469Phase 14 sites๐Ÿ“ Houston๐Ÿ“ San Antonio๐Ÿ“ West Valley City ProteinQure Inc. ยท Tests: PQ203 A Study of MR001 in Patients With Locally Recurrent or Metastatic Advanced Triple-Negative Breast Cancer (TNBC) NCT07208149Phase 1, Phase 21 site๐Ÿ“ Beijing Shenzhen Majory Biotechnology Co., Ltd. ยท Tests: MR001 Bispecific Antibody for Injection A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors NCT07115043Phase 1, Phase 213 sites๐Ÿ“ Grand Rapids๐Ÿ“ St Louis๐Ÿ“ Pittsburgh AstraZeneca ยท Tests: AZD6750, rilvegostomig A Study of NX-1607 in Adults With Advanced Malignancies NCT05107674Phase 117 sites๐Ÿ“ Duarte๐Ÿ“ Los Angeles๐Ÿ“ San Francisco Nurix Therapeutics, Inc. ยท Tests: NX-1607, Paclitaxel The Efficacy and Safety of Utidelone Plus Tirelizumab and Bevacizumab for Advanced or Metastatic Triple-negative Breast Cancer (UTILIZABLE) ๏ผšSingle-arm, Prospective, Open Clinical Study NCT06125080Phase 21 site๐Ÿ“ Wuhan Huihua Xiong ยท Tests: Utidelone, Tirelizumab, Bevacizumab First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies NCT05627960Phase 11 site๐Ÿ“ Baltimore A&G Pharmaceutical Inc. ยท Tests: AG-01 Compound The Optimal Radioimmunotherapy Combinations for Advanced TNBC NCT06735131Phase 21 site๐Ÿ“ Guangzhou Sun Yat-sen University ยท Tests: radiotherapy 5 Gy ร— 5 fractions, once a day, radiotherapy 8 Gy ร— 5 fractions, once a day, radiotherapy 8 Gy ร— 3 fractioโ€ฆ A Study on the Efficacy and Safety of Oral All-trans Retinoic Acid Combined With Toripalimab in TNBC. NCT06371274NA1 site๐Ÿ“ Hangzhou First Affiliated Hospital of Zhejiang University ยท Tests: ATRA, Toripalimab Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001) NCT05579366Phase 1, Phase 266 sites๐Ÿ“ Phoenix๐Ÿ“ Tucson๐Ÿ“ Los Angeles Genmab ยท Tests: Rina-S, Carboplatin, Bevacizumab, Pembrolizumab, Erythromycin ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer NCT06224673Phase 21 site๐Ÿ“ San Francisco Laura Huppert, MD, BA ยท Tests: ARX788, Computed Tomography (CT), Biospecimen Collection, Amiloride A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors NCT06465069Phase 139 sites๐Ÿ“ Duarte๐Ÿ“ La Jolla๐Ÿ“ Los Angeles Eli Lilly and Company ยท Tests: LY4052031, Pembrolizumab Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast Cancer NCT06889688Phase 37 sites๐Ÿ“ Guangzhou๐Ÿ“ Guiyang๐Ÿ“ Wuhan Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University ยท Tests: Camrelizumab+Apatinib+Eribulin, Physician's choice chemotherapy Tier Palliative Care For Patients With Advanced Heart Failure or Cancer NCT07391956NA5 sites๐Ÿ“ Astoria๐Ÿ“ New York๐Ÿ“ New York Icahn School of Medicine at Mount Sinai ยท Tests: Tier-Palliative Care, Community Health Worker TT-702 in Patients With Advanced Solid Tumours. NCT05272709Phase 1, Phase 23 sites๐Ÿ“ London๐Ÿ“ Manchester๐Ÿ“ Southampton Cancer Research UK ยท Tests: TT-702, Anti-PD-1 and PD-L1 agent A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression NCT06682793Phase 1, Phase 210 sites๐Ÿ“ Gilbert๐Ÿ“ La Jolla๐Ÿ“ Los Angeles A2 Biotherapeutics Inc. ยท Tests: A2B395, xT CDx with HLA-LOH assay Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies NCT07064018Phase 1, Phase 21 site๐Ÿ“ Orange University of California, Irvine ยท Tests: Spedox-6, Pegfilgrastim, Filgrastim MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors NCT05076760Phase 12 sites๐Ÿ“ Tampa๐Ÿ“ Durham Memgen, Inc. ยท Tests: MEM-288 Intratumoral Injection, Nivolumab, Docetaxel Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer NCT07137416Phase 12 sites๐Ÿ“ Boston๐Ÿ“ St Louis National Cancer Institute (NCI) ยท Tests: Biopsy Procedure, Biospecimen Collection, Echocardiography Test, Multigated Acquisition Scan, Pidnarulex A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors NCT07020117Phase 114 sites๐Ÿ“ Duarte๐Ÿ“ Irvine๐Ÿ“ Miami Aktis Oncology, Inc. ยท Tests: [225Ac]Ac-AKY-1189 (therapeutic), [64Cu]Cu-AKY-1189 (imaging) Tislelizumab Combined with Nab-Paclitaxel for First-Line Treatment of Advanced Triple-Negative Breast Cancer with Bone Metastasis๏ผŒan Exploratory, Single-Arm, Multicenter Phase II Clinical Study NCT06538896Phase 21 site๐Ÿ“ Hangzhou Zhejiang Cancer Hospital ยท Tests: Tislelizumab + Nab-Paclitaxel, Rankl inhibitor Study of XB010 in Subjects With Solid Tumors NCT06545331Phase 120 sites๐Ÿ“ Irvine๐Ÿ“ Los Angeles๐Ÿ“ Washington D.C. Exelixis ยท Tests: XB010, Pembrolizumab
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy